Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Matinas BioPharma Holdings Inc is a biotechnology business based in the US. Matinas BioPharma shares (MTNB) are listed on the NYSE MKT and all prices are listed in US Dollars. Matinas BioPharma employs 31 staff and has a trailing 12-month revenue of around $1.1 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $0.63 |
|---|---|
| 52-week range | $0.49 - $1.61 |
| 50-day moving average | $0.79 |
| 200-day moving average | $0.79 |
| Wall St. target price | $2.75 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.12 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.629 from 2022-09-23
| 1 week (2022-09-19) | -7.50% |
|---|---|
| 1 month (2022-08-26) | -13.36% |
| 3 months (2022-06-27) | -22.35% |
| 6 months (2022-03-25) | -30.88% |
| 1 year (2021-09-27) | -57.50% |
|---|---|
| 2 years (2020-09-25) | -20.48% |
| 3 years (2019-09-27) | 0.63 |
| 5 years (2017-09-26) | 1.26 |
| Revenue TTM | $1.1 million |
|---|---|
| Gross profit TTM | $-14,549,950 |
| Return on assets TTM | -27.82% |
| Return on equity TTM | -48.11% |
| Profit margin | 0% |
| Book value | $0.20 |
| Market capitalisation | $136.3 million |
TTM: trailing 12 months
We're not expecting Matinas BioPharma to pay a dividend over the next 12 months.
Over the last 12 months, Matinas BioPharma's shares have ranged in value from as little as $0.49 up to $1.61. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Matinas BioPharma's is 1.9996. This would suggest that Matinas BioPharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Matinas BioPharma Holdings, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.